Professor Daniel Thomas
Royal Adelaide Hospital, SA
Dan is a clinical haematologist at the Royal Adelaide Hospital who has a research interest in developing new therapies for myeloid malignancies including myelofibrosis, chronic myelomonocytic leukaemia and acute myeloid leukaemia. His lab has expertise in human primary cell mutation specific assays for drug discovery and accelerating first-in-human clinical trials. He has 9 filed patents and is scientific founder of Boston based company Calytrix Bio. After training as post-doctoral fellow at Stanford University he established the Myeloid Metabolism laboratory which integrates mass spectrometry and genomics to find mutation-specific vulnerabilities. He is currently director of the Blood Cancer Program at SAHMRI, a CSL Centenary Fellow and has authored over 140 publications with editorial roles for Leukemia Research, PloS One and Human Genomics.

